Portland, OR -- (SBWIRE) -- 10/10/2017 -- Spine biologics are used during spine fusion surgery for the treatment of spinal deformities such as trauma, tumors, degenerative disc disease, and spinal cord injuries by stimulating bone growth formation through inflammatory stage, repair stage, and remodeling stage. Therefore, surge in the number of spinal fusion surgeries have fueled the adoption of biologics.

The market is driven by factors such as increase in geriatric population and advantages of biologics such as minimal postoperative time, faster recovery, and ability to activate cellular growth. However, unfavorable reimbursement scenario, higher cost of bone grafts, and ethical issues related to bone grafting procedures hamper the market growth.

Access Full Summary @ https://www.alliedmarketresearch.com/spine-biologics-market

Global spine biologics market generated revenue of $1,644 million in 2015, and is projected to reach $2,214 million by 2022, growing at a CAGR of 4.3% during the forecast period. Spine biologics are used during spine fusion surgery for the treatment of spinal deformities such as trauma, tumors, degenerative disc disease, and spinal cord injuries.

Get 20% discount on this report @ https://www.alliedmarketresearch.com/request-sample/1955

Biologics are used during spinal fusion procedure, as they stimulate bone growth formation through inflammatory stage, repair stage, and remodeling stage. Therefore, rise in number of spinal fusion surgery boosts the use of biologics.

Spine Biologics Market Key Segments:

By Product

-Spinal Allografts
-Bone Graft Substitutes
-Cell based Matrix

By Surgery

-Open Spine Surgery
-Minimally Invasive Spine Surgery